RGO:F:F-Regeneron Pharmaceuticals Inc (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 822.8

Change

+3.40 (+0.41)%

Market Cap

USD 92.42B

Volume

2.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

+3.50 (+3.04%)

USD 525.74B
VX1:F Vertex Pharmaceuticals Incorpo..

+3.50 (+0.93%)

USD 96.61B
CSJ:F CSL Limited

+2.56 (+1.52%)

USD 81.66B
CSJA:F CSL LTD SPON.ADR 2

+0.50 (+0.60%)

USD 78.61B
0QF:F Moderna Inc

+1.48 (+1.34%)

USD 44.82B
UNC0:F UCB S.A. UNSP.ADR 1/2

-1.00 (-1.67%)

USD 23.00B
UNC:F UCB SA

-0.90 (-0.75%)

USD 22.90B
1AEA:F argenx SE

+6.00 (+1.69%)

USD 21.96B
1AE:F Argen-X

+2.20 (+0.61%)

USD 21.73B
22UA:F BioNTech SE

+0.40 (+0.47%)

USD 19.66B

ETFs Containing RGO:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.82% 65% D 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.82% 65% D 53% F
Trailing 12 Months  
Capital Gain 14.04% 75% C 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.04% 75% C 62% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 17.48% 85% B 86% B+
Dividend Return 17.48% 85% B 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 16.90% 78% C+ 65% D
Risk Adjusted Return 103.43% 100% F 97% N/A
Market Capitalization 92.42B 100% F 98% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.